AI-powered search

AAD: Long-Term Safety, Efficacy Seen for Delgocitinib Cream in Hand Eczema

No safety concerns observed during 36 weeks of treatment with delgocitinib cream 20 mg/g

By Dermsquared Editorial Team | March 20, 2024

WEDNESDAY, March 20, 2024 -- For adults with moderate-to-severe chronic hand eczema (CHE), treatment with delgocitinib cream 20 mg/g for 36 weeks yields ongoing improvements, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 8 to 12 in San Diego.

Melinda Gooderham, M.D., from the SKiN Centre for Dermatology in Peterborough, Ontario, Canada, and colleagues examined the long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with moderate-to-severe CHE who completed the 16-week treatment period in the DELTA-1 and DELTA-2 trials. A total of 801 participants were treated on an as-needed basis with twice-daily delgocitinib cream in DELTA-3.

The researchers observed no safety concerns during delgocitinib cream treatment in DELTA-1, DELTA-2, or DELTA-3. The most frequent treatment-emergent adverse events were COVID-19 and nasopharyngitis in DELTA-3. In DELTA-3, improvement from baseline to week 36 continued in Investigator's Global Assessment for CHE clear/almost clear, ≥75 percent/≥90 percent improvement in the Hand Eczema Severity Index, and ≥4-point itch/pain reduction among delgocitinib-treated patients.

"Overall, with delgocitinib cream 20 mg/g treatment, no safety concerns were identified and efficacy further improved, supporting the benefit of long-term as-needed use of delgocitinib cream in patients with CHE," the authors write.

The DELTA trials were sponsored by LEO Pharma, the manufacturer of delgocitinib.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved